Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001208989 | SCV001380407 | pathogenic | not provided | 2023-04-28 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 939569). This premature translational stop signal has been observed in individual(s) with choreoacanthocytosis (PMID: 21598378, 24974674). This variant is present in population databases (rs771943305, gnomAD 0.008%). This sequence change creates a premature translational stop signal (p.Arg731*) in the VPS13A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VPS13A are known to be pathogenic (PMID: 12404112, 21598378). |
Gene |
RCV001208989 | SCV005201616 | pathogenic | not provided | 2024-01-07 | criteria provided, single submitter | clinical testing | Reported with a second VPS13A variant, phase unknown, in a patient with chorea-acanthocytosis (PMID: 21598378); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 21598378, 24974674) |
Natera, |
RCV001828675 | SCV002078234 | pathogenic | Chorea-acanthocytosis | 2020-08-15 | no assertion criteria provided | clinical testing |